Skip to main content
Erschienen in: Neurological Sciences 4/2015

01.04.2015 | Original Article

MCP-1 and CCR2 gene polymorphisms in Parkinson’s disease in a Han Chinese cohort

verfasst von: Liang Gao, Hongmei Tang, Kun Nie, Limin Wang, Jiehao Zhao, Rong Gan, Jing Huang, Shujun Feng, Ruiming Zhu, Zhenpeng Duan, Youwen Zhang, Xin Zhao, Yuhu Zhang, Lijuan Wang

Erschienen in: Neurological Sciences | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Monocyte chemoattractant protein-1 (MCP-1) and its receptor CC chemokine receptor-2 (CCR2) play important roles in neuroinflammation and they have been shown to be involved in Parkinson’s disease (PD) pathogenesis. In addition, several studies have suggested a role for the MCP-1 and CCR2 genotypes in cognitive impairment and depression, which are common non-motor symptoms in PD patients. In this study, a cohort of 521 PD patients and 556 cases of healthy controls were recruited to investigate the association between the MCP-1 2518A/G (rs1064211) and CCR2 V64I (rs1799864) gene polymorphisms and PD risk in the Chinese population. We also analyze the influence of these genotypes on the cognitive function and depression in PD patients by comparing Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Wechsler Adult Intelligence Scale-Chinese Revision (WAIS-RC), Wechsler Memory Scale-Chinese Revision (WMS-RC) and Hamilton Depression Rating Scale (HAMD) ratings in 217 PD patients. Our results showed no significant differences in the genotype frequency between the PD group and the control group (P > 0.05). In addition, we also failed to find an influence of the MCP-1 and CCR2 genotypes on MMSE scores, MoCA scores, WAIS-RC scores, WMS-RC scores and HAMD scores in PD patients (P > 0.05). The MCP-1 and CCR2 gene polymorphisms may not be genetic risk factors for PD in the Han Chinese population, and they do not appear to influence cognitive function and depression in PD patients.
Literatur
1.
Zurück zum Zitat Kannarkat GT, Boss JM, Tansey MG (2013) The role of innate and adaptive immunity in Parkinson’s disease. J Parkinsons Dis 3:493–514PubMedCentralPubMed Kannarkat GT, Boss JM, Tansey MG (2013) The role of innate and adaptive immunity in Parkinson’s disease. J Parkinsons Dis 3:493–514PubMedCentralPubMed
2.
Zurück zum Zitat Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, van Noort JM (2013) Inflammation in neurodegenerative diseases—an update. Immunology 142:151–166CrossRef Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, van Noort JM (2013) Inflammation in neurodegenerative diseases—an update. Immunology 142:151–166CrossRef
3.
Zurück zum Zitat Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G (2001) Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 22:147–184CrossRefPubMed Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G (2001) Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 22:147–184CrossRefPubMed
4.
Zurück zum Zitat Bose S, Cho J (2013) Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Arch Pharm Res 36:1039–1050CrossRefPubMed Bose S, Cho J (2013) Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Arch Pharm Res 36:1039–1050CrossRefPubMed
5.
Zurück zum Zitat Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C (2010) The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224:93–100CrossRefPubMed Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C (2010) The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224:93–100CrossRefPubMed
6.
Zurück zum Zitat Pattarini R, Smeyne RJ, Morgan JI (2007) Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson’s disease. Neuroscience 145:654–668PubMedCentralCrossRefPubMed Pattarini R, Smeyne RJ, Morgan JI (2007) Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson’s disease. Neuroscience 145:654–668PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23:55–63CrossRefPubMed Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23:55–63CrossRefPubMed
8.
Zurück zum Zitat Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O (2013) Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183–189CrossRefPubMed Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O (2013) Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183–189CrossRefPubMed
9.
Zurück zum Zitat Nishimura M, Kuno S, Mizuta I, Ohta M, Maruyama H, Kaji R, Kawakami H (2003) Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson’s disease. Mov Disord 18:953–955CrossRefPubMed Nishimura M, Kuno S, Mizuta I, Ohta M, Maruyama H, Kaji R, Kawakami H (2003) Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson’s disease. Mov Disord 18:953–955CrossRefPubMed
10.
Zurück zum Zitat Pola R, Flex A, Gaetani E, Proia AS, Papaleo P, Di Giorgio A et al (2004) Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer’s disease in Italians. Exp Gerontol 39:1249–1252CrossRefPubMed Pola R, Flex A, Gaetani E, Proia AS, Papaleo P, Di Giorgio A et al (2004) Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer’s disease in Italians. Exp Gerontol 39:1249–1252CrossRefPubMed
11.
Zurück zum Zitat Galimberti D, Fenoglio C, Lovati C, Gatti A, Guidi I, Venturelli E et al (2004) CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer’s disease. J Neurol Sci 225:79–83CrossRefPubMed Galimberti D, Fenoglio C, Lovati C, Gatti A, Guidi I, Venturelli E et al (2004) CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer’s disease. J Neurol Sci 225:79–83CrossRefPubMed
12.
Zurück zum Zitat Pae CU, Chung KI, Kim JJ, Yu HS, Lee CU, Lee SJ et al (2004) Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. Psychiatr Genet 14:65–67CrossRefPubMed Pae CU, Chung KI, Kim JJ, Yu HS, Lee CU, Lee SJ et al (2004) Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. Psychiatr Genet 14:65–67CrossRefPubMed
13.
Zurück zum Zitat Daniel SE, Lees AJ (1993) Parkinson’s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165–172PubMed Daniel SE, Lees AJ (1993) Parkinson’s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165–172PubMed
14.
Zurück zum Zitat Nie K, Zhang Y, Gan R, Wang L, Zhao J, Huang Z et al (2013) Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson’s disease with cognitive impairment in the Han Chinese population. Neurosci Lett 541:111–115CrossRefPubMed Nie K, Zhang Y, Gan R, Wang L, Zhao J, Huang Z et al (2013) Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson’s disease with cognitive impairment in the Han Chinese population. Neurosci Lett 541:111–115CrossRefPubMed
15.
Zurück zum Zitat Guyon A, Skrzydelski D, De Giry I, Rovere C, Conductier G, Trocello JM et al (2009) Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience 162:1072–1080CrossRefPubMed Guyon A, Skrzydelski D, De Giry I, Rovere C, Conductier G, Trocello JM et al (2009) Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience 162:1072–1080CrossRefPubMed
16.
Zurück zum Zitat Huerta C, Alvarez V, Mata IF, Coto E, Ribacoba R, Martinez C et al (2004) Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer’s and Parkinson’s disease. Neurosci Lett 370:151–154CrossRefPubMed Huerta C, Alvarez V, Mata IF, Coto E, Ribacoba R, Martinez C et al (2004) Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer’s and Parkinson’s disease. Neurosci Lett 370:151–154CrossRefPubMed
17.
Zurück zum Zitat Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844CrossRefPubMed Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844CrossRefPubMed
18.
Zurück zum Zitat Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One 7:e30525PubMedCentralCrossRefPubMed Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One 7:e30525PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Harries LW, Bradley-Smith RM, Llewellyn DJ, Pilling LC, Fellows A, Henley W et al (2012) Leukocyte CCR2 expression is associated with mini-mental state examination score in older adults. Rejuvenation Res 15:395–404PubMedCentralCrossRefPubMed Harries LW, Bradley-Smith RM, Llewellyn DJ, Pilling LC, Fellows A, Henley W et al (2012) Leukocyte CCR2 expression is associated with mini-mental state examination score in older adults. Rejuvenation Res 15:395–404PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Zhang R, Miller RG, Madison C, Jin X, Honrada R, Harris W et al (2013) Systemic immune system alterations in early stages of Alzheimer’s disease. J Neuroimmunol 256:38–42PubMedCentralCrossRefPubMed Zhang R, Miller RG, Madison C, Jin X, Honrada R, Harris W et al (2013) Systemic immune system alterations in early stages of Alzheimer’s disease. J Neuroimmunol 256:38–42PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B et al (2006) Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease. Neurobiol Aging 27:1763–1768CrossRefPubMed Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B et al (2006) Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease. Neurobiol Aging 27:1763–1768CrossRefPubMed
22.
Zurück zum Zitat Porcellini E, Ianni M, Carbone I, Franceschi M, Licastro F (2013) Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer’s disease. Immun Ageing 10:6PubMedCentralCrossRefPubMed Porcellini E, Ianni M, Carbone I, Franceschi M, Licastro F (2013) Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer’s disease. Immun Ageing 10:6PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S et al (2004) MCP-1 in Alzheimer’s disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 25:1169–1173CrossRefPubMed Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S et al (2004) MCP-1 in Alzheimer’s disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 25:1169–1173CrossRefPubMed
24.
Zurück zum Zitat Combarros O, Infante J, Llorca J, Berciano J (2004) No evidence for association of the monocyte chemoattractant protein-1 (-2518) gene polymorphism and Alzheimer’s disease. Neurosci Lett 360:25–28CrossRefPubMed Combarros O, Infante J, Llorca J, Berciano J (2004) No evidence for association of the monocyte chemoattractant protein-1 (-2518) gene polymorphism and Alzheimer’s disease. Neurosci Lett 360:25–28CrossRefPubMed
25.
Zurück zum Zitat Khorram Khorshid HR, Manoochehri M, Nasehi L, Ohadi M, Rahgozar M, Kamali R (2012) Ccr2-64i and Ccr5 Delta32 Polymorphisms in Patients with Late-Onset Alzheimer’s disease; A Study from Iran (Ccr2-64i And Ccr5 Delta32 Polymorphisms in Alzheimer’s disease). Iran J Basic Med Sci 15:937–944PubMedCentralPubMed Khorram Khorshid HR, Manoochehri M, Nasehi L, Ohadi M, Rahgozar M, Kamali R (2012) Ccr2-64i and Ccr5 Delta32 Polymorphisms in Patients with Late-Onset Alzheimer’s disease; A Study from Iran (Ccr2-64i And Ccr5 Delta32 Polymorphisms in Alzheimer’s disease). Iran J Basic Med Sci 15:937–944PubMedCentralPubMed
26.
Zurück zum Zitat van Zuiden M, Heijnen CJ, van de Schoot R, Amarouchi K, Maas M, Vermetten E et al (2011) Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: a prospective, longitudinal study. PLoS One 6:e29142PubMedCentralCrossRefPubMed van Zuiden M, Heijnen CJ, van de Schoot R, Amarouchi K, Maas M, Vermetten E et al (2011) Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: a prospective, longitudinal study. PLoS One 6:e29142PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H et al (2009) Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry 10:313–323CrossRefPubMed Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H et al (2009) Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry 10:313–323CrossRefPubMed
28.
Zurück zum Zitat Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH et al (2008) A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 18:230–233PubMedCentralCrossRefPubMed Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH et al (2008) A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 18:230–233PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O et al (2007) Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007:76396PubMedCentralCrossRefPubMed Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O et al (2007) Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007:76396PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Altamura AC, Mundo E, Cattaneo E, Pozzoli S, Dell’osso B, Gennarelli M et al (2010) The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study. Neuroimmunomodulation 17:126–131CrossRefPubMed Altamura AC, Mundo E, Cattaneo E, Pozzoli S, Dell’osso B, Gennarelli M et al (2010) The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study. Neuroimmunomodulation 17:126–131CrossRefPubMed
Metadaten
Titel
MCP-1 and CCR2 gene polymorphisms in Parkinson’s disease in a Han Chinese cohort
verfasst von
Liang Gao
Hongmei Tang
Kun Nie
Limin Wang
Jiehao Zhao
Rong Gan
Jing Huang
Shujun Feng
Ruiming Zhu
Zhenpeng Duan
Youwen Zhang
Xin Zhao
Yuhu Zhang
Lijuan Wang
Publikationsdatum
01.04.2015
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 4/2015
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-014-1990-3

Weitere Artikel der Ausgabe 4/2015

Neurological Sciences 4/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.